the years, the regulatory landscape has evolved to accommodate the unique characteristics of nucleic acid therapies. However, navigating this evolving regulatory landscape remains complex, requiring rigorous preclinical testing, robust clinical trials, and close collaboration between industry stakeholders and regulatory authorities. Despite the challenges, as of 2023, 18 nucleic acid therapies have made it to[…]